National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Telavancin (Vibativ®)

Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv® should be used only in situations where it is known or suspected that other alternatives are not suitable.

 

Rapid Review

Commenced Completed Outcome
08/12/2014 13/01/2015 Full Pharmacoeconomic Evaluation Not Recommended